So Yeon Kim
30 posts
So Yeon Kim
@Sokim_33
Thoracic oncology | Phase I @YaleCancer | @MontefioreNYC alum | @TuftsMedicalCtr alum | @Princeton alum
Katılım Eylül 2020
334 Takip Edilen242 Takipçiler
Honored to step into the role of Director of Thoracic Oncology. Big shoes to fill following Dr. Liu’s leadership. Grateful for the trust and support - excited to work with this amazing team to provide the best care and drive cutting-edge research
@LombardiCancer @StephenVLiu
Stephen V Liu, MD@StephenVLiu
I am extremely fortunate that one of my first acts as @Georgetown Hematology & Oncology Division Chief is to announce Dr. Chul Kim as the new Director of Thoracic Oncology. @chulkimMD has been essential to the success of our thoracic clinical and research program and I look forward to watching him grow our program in the coming years.
English
So Yeon Kim retweetledi
Phase 3 #HERTHENA-Lung02 study:
▫️HER3-DXd v chemo in EGFRm NSCLC post 3G TKI
▫️mPFS: 5.8 v 5.4 mo (HR 0.77)
▫️ORR: 35% v 25%
▫️🧠PFS: 5.4 v 4.2 mo (HR 0.75)
▫️TEAEs G≥3: 73% v 57%, mostly thrombocytopenia
▫️5% ILD (w/ 2 G5 events)
#ASCO25 @EGFRResisters @OncoAlert
So Yeon Kim retweetledi
In this #LungCancerConsidered, we discussed in Korean emerging treatments for EGFR+ and HER2+ mutant NSCLC as well as SCLC.
Grateful to Dr. @Sokim_33 and Dr. Se-Hoon Lee for sharing their expert insights!
많은 청취 부탁드립니다.
Listen here:
bit.ly/LCCKor25
IASLC@IASLC
What’s new in lung cancer research from Korea? In this Korean-language #LungCancerConsidered episode, @chulkimMD speaks with @sokim_33 and @SeHoonLee14087 about EGFR/HER2 mutant NSCLC and SCLC. 🎧 Listen now: bit.ly/LCCKor25 #LungCancer #Korea
English
So Yeon Kim retweetledi
Interested in an updated overview of small cell lung cancer geared towards a general audience? Check out our review article published in JAMA! @Sokim_33 @Annechiangmd @YaleMed @YaleCancer @YaleRadOnc
JAMA@JAMA_current
Small cell lung cancer (SCLC) is a smoking-related malignancy that presents at an advanced stage in 70% of patients. This narrative review summarizes the epidemiology, molecular characteristics, clinical presentation, and management of SCLC. ja.ma/4j5YgRF
English
So Yeon Kim retweetledi
Getting COVID at the top of the New Year was what I originally considered a nuisance, impediment, and ultimately a obstruction to all the goals I had set out for 2025, but when I paused I realized some incredibly important 💡 moments. 🧵1/6
English
Our attempt at the Ellen ‘Oscar selfie’ at the @JTOonline reviewer workshop before leaving San Diego!
Thank you to the faculty @DrAlexAdjei @KarenReckampMD @oncoOuLungCA @vs_lim for such an amazing last day at #WCLC24
@IASLC #lcsm
English
@vs_lim @rajatthawani @JTOonline @DrAlexAdjei @KarenReckampMD @oncoOuLungCA @IASLC @LeiDeng3 @c_vakka @IvyLorena_Md Thank you for a wonderful workshop!
English
@rajatthawani @JTOonline @DrAlexAdjei @KarenReckampMD @oncoOuLungCA @IASLC @Sokim_33 @LeiDeng3 @c_vakka @IvyLorena_Md This is amazing! We need to recreate this with a “revised version”! Welcome on board as JTO and JTO CRR trained reviewers!
English
So Yeon Kim retweetledi
Data on Dato- encouraging! businesswire.com/news/home/2023…
English
So Yeon Kim retweetledi
The efficacy of #immunotherapy is mainly attributed to reactivation of CD8+ T cells that specifically recognize tumour antigens in a MHC-I-context. There is new evidence that CD4+ T cells can contribute to antitumour immunity, independent of their role as helpers and regulators of CD8+ cytolytic T cells. CD4+ T cells were shown preclinically capable of eradicating tumour cells that do not express MHC-II by mobilizing myeloid cells. nature.com/articles/s4158…
English
So Yeon Kim retweetledi
About last night. A feast! They had to place a small table behind us for additional food plates which didn’t fit on the table. Amr knows how to welcome the guests to Cleveland!
It’s been fun!
@NANETS1
English
So Yeon Kim retweetledi
An analysis by @Sokim_33 @AminNassarMD & colleagues of treatment options for patients with stage III unresectable EGFR mutant #NSCLC showed consolidation EGFR TKI therapy yielded significantly longer disease free survival than durvalumab #ASCO23 #lcsm @SmilowCancer @YaleMed @YNHH
English
So Yeon Kim retweetledi
#AACR23 Is #AEGEAN a sea change?
- Ph III neodj durva+chemo + 1yr durva post surgery v chemo alone in early stage NSCLC
- 70% stage III
- EFS HR 0.68, pCR 17% v 4%
- cis or carbo had equiv EFS
- ?females did not do as well for EFS or pCR - more data needed
@OncoAlert #LCSM
English
@LeciaSequist Aw, it was so wonderful to meet you! Thank you and very much enjoyed your talk!
English
Thank you @politikaterina & Sarah Goldberg for inviting me to speak @YaleCancer Thoracic Cancers Seminar! Two uber talented #WomenLeaders + superb faculty like @Annechiangmd @MJGrantMD @Sokim_33 Dan Boffa, Scott Gettinger & Rick Wilson. It was a pleasure & honor to meet everyone
English
So Yeon Kim retweetledi
2 for the price of..0!
Cambridge Press Elements in Molecular Oncology chapters on precision oncology in NSCLC- EGFR + beyond -available for download for free for 1 wk before paywall comes up
cambridge.org/core/publicati…
English
So Yeon Kim retweetledi
BFAST but be smart! @DrRoyHerbstYale & @Sokim_33 discuss results of a phase III trial evaluating blood-based tumor mutational burden in patients with treatment-naive advanced-stage #NSCLC in @NatureRevCancer. #lcsm @OncoAlert @SmilowCancer @YaleMed @YNHH
nature.com/articles/s4157…
English
Credits to the whole team! @DrSteveMartin @slowwalker919 @StephenVLiu @HaiyingCheng @PatrickCMa1 @chulkimMD @ReckampK @dipeshuprety4 @MNagasaka
Stephen V Liu, MD@StephenVLiu
#NACLC22 Dr. @maryjofidlerMD discusses targeted agents for #METex14 NSCLC, highlighting work from Dr. @Sokim_33 in #JTOCRR
English
@DrSteveMartin @StephenVLiu @PatrickCMa1 @MNagasaka @dipeshuprety4 @chulkimMD @HaiyingCheng @Joanne_XXA @ReckampK Congratulations @DrSteveMartin and @Sokim_33 ! Great team work and privileged to be part of this study with the @CARISPOA.
English
Thx, Steve!
533(!) METex14+ NSCLC cases➡️maybe a MET-analysis?
Work led by super🌟fellow➡️Yale faculty @Sokim_33+ Jun Yin aka @slowwalker919 who walks thru genomics ultra fast!
Founded on 👇 @CR_AACR paper to prove METex14-driven pathways defined in lab
twitter.com/DrSteveMartin/…
Stephen V Liu, MD@StephenVLiu
Extensive characterization of #METex14 NSCLC in #JTOCRR by Drs. @Sokim_33 @DrSteveMartin. Included 21582 samples tested with NGS: METex14 seen in 533 (2.5%). Analysis noted common co-alterations in MDM2, HMGA2, CDK4 more common in MET altered vs wild type. jtocrr.org/article/S2666-…
English
Extensive characterization of #METex14 NSCLC in #JTOCRR by Drs. @Sokim_33 @DrSteveMartin. Included 21582 samples tested with NGS: METex14 seen in 533 (2.5%). Analysis noted common co-alterations in MDM2, HMGA2, CDK4 more common in MET altered vs wild type.
jtocrr.org/article/S2666-…
English